Salt Lake City--New research shows that men with clinically localized prostate cancer who are treated to high dose levels with three-dimensional conformal radiation therapy achieve long-term PSA relapse-free survival with minimal side effects.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.